Poolbeg Pharma plc Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)Market opportunity estimated to be greater than US$1 billion Key highlights Efficacy demonstrated in reducing cancer immunotherapy-induced CRS in an in vivo modelData strengthens an.
Poolbeg's cytokine release syndrome drug shows potential pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Novacyt SA on Tuesday named Steve Gibson as its new chief financial officer, with immediate effect.
Novacyt is an Eastleigh-based biotechnology group focused on clinical diagnostics.
Gibson joined.